Valacyclovir for herpes simplex virus infection: long-term safety and sustained efficacy after 20 years' experience with acyclovir
- PMID: 12353186
- DOI: 10.1086/342966
Valacyclovir for herpes simplex virus infection: long-term safety and sustained efficacy after 20 years' experience with acyclovir
Abstract
An extensive clinical trial program combined with 5 years' postmarketing experience with valacyclovir provides evidence of favorable safety and efficacy in herpes simplex virus (HSV) management. Valacyclovir enhances acyclovir bioavailability compared with orally administered acyclovir. Long-term use of acyclovir for up to 10 years for HSV suppression is effective and well tolerated. Acyclovir is also approved for use in children, is available in some countries over the counter in cream formulation for herpes labialis, and has been monitored in over 1000 pregnancies. Safety monitoring data from clinical trials of valacyclovir, involving over 3000 immunocompetent and immunocompromised persons receiving long-term therapy for HSV suppression, were analyzed. Safety profiles of valacyclovir (</=1000 mg/day), acyclovir (800 mg/day), and placebo were similar. Extensive sensitivity monitoring of HSV isolates confirmed a very low rate of acyclovir resistance among immunocompetent subjects (<0.5%). The incidence of resistance among immunocompromised patients remains low at about 5%.
Similar articles
-
Efficacy and safety of valacyclovir for the suppression and episodic treatment of herpes simplex virus in patients with HIV.Clin Infect Dis. 2004 Nov 1;39 Suppl 5:S258-66. doi: 10.1086/422362. Clin Infect Dis. 2004. PMID: 15494897 Clinical Trial.
-
Valacyclovir for the treatment of genital herpes.Expert Rev Anti Infect Ther. 2006 Jun;4(3):367-76. doi: 10.1586/14787210.4.3.367. Expert Rev Anti Infect Ther. 2006. PMID: 16771614 Review.
-
The effect of daily valacyclovir suppression on herpes simplex virus type 2 viral shedding in HSV-2 seropositive subjects without a history of genital herpes.Sex Transm Dis. 2008 Mar;35(3):286-90. doi: 10.1097/OLQ.0b013e31815b0132. Sex Transm Dis. 2008. PMID: 18157071 Clinical Trial.
-
Effect of valacyclovir on viral shedding in immunocompetent patients with recurrent herpes simplex virus 2 genital herpes: a US-based randomized, double-blind, placebo-controlled clinical trial.Mayo Clin Proc. 2006 Oct;81(10):1321-7. doi: 10.4065/81.10.1321. Mayo Clin Proc. 2006. PMID: 17036557 Clinical Trial.
-
Herpes simplex virus infection.Semin Pediatr Infect Dis. 2002 Jan;13(1):6-11. doi: 10.1053/spid.2002.29752. Semin Pediatr Infect Dis. 2002. PMID: 12118847 Review.
Cited by
-
Clinical and therapeutic issues for herpes simplex virus-2 and HIV co-infection.Drugs. 2007;67(2):155-74. doi: 10.2165/00003495-200767020-00001. Drugs. 2007. PMID: 17284082 Review.
-
Treatment of herpes simplex virus infections in pediatric patients: current status and future needs.Clin Pharmacol Ther. 2010 Nov;88(5):720-4. doi: 10.1038/clpt.2010.192. Epub 2010 Sep 29. Clin Pharmacol Ther. 2010. PMID: 20881952 Free PMC article.
-
Nanostructures for the Inhibition of Viral Infections.Molecules. 2015 Aug 3;20(8):14051-81. doi: 10.3390/molecules200814051. Molecules. 2015. PMID: 26247927 Free PMC article. Review.
-
Gynecologic issues in the HIV-infected woman.Infect Dis Clin North Am. 2008 Dec;22(4):709-739. doi: 10.1016/j.idc.2008.05.006. Infect Dis Clin North Am. 2008. PMID: 18954760 Free PMC article. Review.
-
Human immunodeficiency virus/acquired immunodeficiency syndrome and infertility: emerging problems in the era of highly active antiretrovirals.Fertil Steril. 2011 Sep;96(3):546-53. doi: 10.1016/j.fertnstert.2011.05.094. Epub 2011 Jun 30. Fertil Steril. 2011. PMID: 21722892 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical